Skip to main content

ALSUntangled #67: rituximab.

Publication ,  Journal Article
Li, X; Armon, C; Barkhaus, P; Barnes, B; Benatar, M; Bertorini, T; Bromberg, M; Carter, GT; Crayle, J; Cudkowicz, M; Dimachkie, M; Feldman, EL ...
Published in: Amyotroph Lateral Scler Frontotemporal Degener
August 2023

ALSUntangled reviews alternative and off-label treatments on behalf of people with ALS who ask about them. Here we review rituximab, a drug which specifically depletes B lymphocytes. We show a current lack of evidence for a role of these cells in ALS progression. The one patient we found who described using Rituximab for their ALS found no benefit. Given all this, and the known serious risks of rituximab, we advise against its use as an ALS treatment.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Amyotroph Lateral Scler Frontotemporal Degener

DOI

EISSN

2167-9223

Publication Date

August 2023

Volume

24

Issue

5-6

Start / End Page

544 / 547

Location

England

Related Subject Headings

  • Rituximab
  • Off-Label Use
  • Humans
  • Amyotrophic Lateral Sclerosis
  • 3209 Neurosciences
  • 1109 Neurosciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Li, X., Armon, C., Barkhaus, P., Barnes, B., Benatar, M., Bertorini, T., … Bedlack, R. (2023). ALSUntangled #67: rituximab. Amyotroph Lateral Scler Frontotemporal Degener, 24(5–6), 544–547. https://doi.org/10.1080/21678421.2022.2122845
Li, Xiaoyan, Carmel Armon, Paul Barkhaus, Benjamin Barnes, Michael Benatar, Tulio Bertorini, Mark Bromberg, et al. “ALSUntangled #67: rituximab.Amyotroph Lateral Scler Frontotemporal Degener 24, no. 5–6 (August 2023): 544–47. https://doi.org/10.1080/21678421.2022.2122845.
Li X, Armon C, Barkhaus P, Barnes B, Benatar M, Bertorini T, et al. ALSUntangled #67: rituximab. Amyotroph Lateral Scler Frontotemporal Degener. 2023 Aug;24(5–6):544–7.
Li, Xiaoyan, et al. “ALSUntangled #67: rituximab.Amyotroph Lateral Scler Frontotemporal Degener, vol. 24, no. 5–6, Aug. 2023, pp. 544–47. Pubmed, doi:10.1080/21678421.2022.2122845.
Li X, Armon C, Barkhaus P, Barnes B, Benatar M, Bertorini T, Bromberg M, Carter GT, Crayle J, Cudkowicz M, Dimachkie M, Feldman EL, Glass J, Goslinga J, Heiman-Patterson T, Jhooty S, Lichtenstein R, Lund I, Mcdermott C, Pattee G, Pierce K, Ratner D, Salmon K, Wicks P, Bedlack R. ALSUntangled #67: rituximab. Amyotroph Lateral Scler Frontotemporal Degener. 2023 Aug;24(5–6):544–547.

Published In

Amyotroph Lateral Scler Frontotemporal Degener

DOI

EISSN

2167-9223

Publication Date

August 2023

Volume

24

Issue

5-6

Start / End Page

544 / 547

Location

England

Related Subject Headings

  • Rituximab
  • Off-Label Use
  • Humans
  • Amyotrophic Lateral Sclerosis
  • 3209 Neurosciences
  • 1109 Neurosciences
  • 1103 Clinical Sciences